Fundamental Analysis of Tatva Chintan Pharma Chem Ltd. - Growth / Value Index
TATVA - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.56
Very Expensive - Price to Intrinsic Value of 3.59
Price to Earning Ratio is 444.66 and EV to EBITDA is 77.75 suggesting that it is very expensive
Price to Book Ratio of 4.31 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 465.10 | 277.52 | 107.40 % | ||
| Price to Book | 4.51 | 2.14 | 0 % | 2.25 | |
| Price to Sales | 8.45 | 4.14 | -86.04 % | ||
| Enterprise Value to EBITDA Multiple | 44.06 | -89.40 % |
TATVA - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Net profit has jumped from negative to positive
Excellent QoQ /QoQ FY EPS growth
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
Steady Growth in EPS for last four quarters
Very Low Dividend Yield of 0 %
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 0.970 | 0.773 | 0 % | 0.900 | |
| Return On Asset | 0.872 | 0.683 | 0 % | 0.795 | |
| Net Profit Margin | 1.82 | 1.49 | 288.74 % | 5.69 | |
| Operating Profit Margin | 28.06 | 1.37 | -98.63 % | 14.83 | |
| EBITDA Margin | 10.46 | 9.55 | 33.71 % | 15.81 |
Highlights
| Market Cap | 33270.52 M |
| Enterprise Value | 33520.66 M |
| Price/Book TTM | 4.51 |
| Outstanding Share | 23392.06 K |
| Float/ Outstanding Share | 28.01% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 9.65 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 21.74 |
| Sloan Ratio | 0.055 |
| Peter Lynch Fair Value | 0 |
TATVA - Growth Highlights
Growth Analysis
Short term positive trend in total sale and net profit
STRONG JUMP IN NET SALE : YoY growth
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Very Poor Score of 14.58
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 394.11 (Cr) | 358.39 % | 8.34 % |
| Gross Profit | 174.07 (Cr) | % | 16.62 % |
| EBITDA | 41.23 (Cr) | 512.92 % | 90.91 % |
| Net Profit | 7.16 (Cr) | 965.15 % | 545.63 % |
| EPS | 3.06 | 971.43 % | NA |
TATVA - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 87.50
Altman Z Score of 20.84 suggests good Stability
Company is unable to generate enough free cash to support the business.
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.0493 | 0 % | 0.0493 | |
| Cash Ratio | 0.147 | 0 % | ||
| Quick Ratio | 1.37 | 0 % | 1.37 | |
| Shareholders Equity | 88.35 | 0 % | ||
| Debt to EBITDA | 0.996 | 0 % |
Historical Valuation Ratios of Tatva Chintan Pharma Chem Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Tatva Chintan Pharma Chem Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Tatva Chintan Pharma Chem Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Tatva Chintan Pharma Chem Ltd.
Historical Solvency Ratios
Loading ...
Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech Charts